株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マラリアワクチン市場規模:作用因子別、ワクチンタイプ別、流通チャネル別、地域別セグメントおよび予測

Malaria Vaccines Market Size Report By Agent; By Vaccines Type; By Channel of Distribution; By Regions Segments & Forecast, 2019 - 2026

発行 Polaris Market Research 商品コード 873283
出版日 ページ情報 英文 210 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
マラリアワクチン市場規模:作用因子別、ワクチンタイプ別、流通チャネル別、地域別セグメントおよび予測 Malaria Vaccines Market Size Report By Agent; By Vaccines Type; By Channel of Distribution; By Regions Segments & Forecast, 2019 - 2026
出版日: 2019年03月01日 ページ情報: 英文 210 Pages
概要

当レポートでは、世界のマラリアワクチン市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 概要と調査範囲

第2章 エグゼクティブサマリー

第3章 市場動向

  • 業界概要
  • 生態系分析
  • 市場動向
  • ポーターズファイブフォース
  • PEST分析
  • バリューチェーン分析
  • 業界動向
  • 競合ランキング分析

第4章 作用因子別市場規模と予測

  • 調査結果
  • 熱帯熱マラリア原虫
  • 三日熱マラリア原
  • ハマダラカ種

第5章 ワクチンタイプ別市場規模と予測

  • 調査結果
  • 前赤血球ワクチン
  • 赤血球ワクチン
  • 多重抗原ワクチン

第6章 流通チャネル別市場規模と予測

  • 調査結果
  • 病院
  • クリニック
  • コミュニティセンター

第7章 地域別市場規模と予測

  • 調査結果
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 企業プロファイル

  • GlaxoSmithKline
  • GenVec, Inc.
  • Nobelpharma
  • Sanaria
  • Cadila Healthcare Ltd.
  • VLP Therapeutics LLC
  • CellFree Sciences Co. Ltd.
  • Genome ReS Ltd.
目次
Product Code: PM1525

The global malaria vaccines market is expected to reach USD 134.9 million by 2026 growing at a CAGR of 33.2% during the forecast period according to a new study published by Polaris Market Research. The report 'Malaria Vaccines Market Size Report By Agent (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species); By Vaccines Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, Multi-antigen Vaccine); By Channel of Distribution (Hospitals, Clinics, Community Centers); By Regions: Segment Forecast, 2019 - 2026' provides an extensive analysis of present market dynamics and predicted future trends.

According to the World Malaria Report published by WHO in November 2018, the cases for malaria were 219 million in 2017 in more than 90 countries which were up from 217 million cases in 2017. The total deaths due to malaria in 2017 were 435,000 which were registered in the malaria affected regions.

This mosquito-borne illness creates extreme disease in kids and in grownups. Expecting females and kids cannot get away from consequences of this fever. It is reported that malaria-affected expecting females offer early birth or occasionally bring to life dead babies. Different precaution to suppress this fever consist of using insect nets and splashing of pesticides. Existing research studies have wrapped up that a) insects are immune to pesticides, b) pesticides have hazardous impacts to human beings, as well as c) malaria fever ends up being immune to medications. Actions to suppress malaria fever progressively reduces.

The market for malaria vaccines globally has been divided based on vaccine type, agent, channel of distribution and region. Considering the vaccine type, the market is bifurcated into pre-erythrocytic vaccine, erythrocytic vaccine, and multi-antigen vaccine. The channel of distribution used for malaria vaccines include the hospitals, clinics and community centers. Considering the agent used in the malaria vaccines, the global market is divided into plasmodium falciparum, anopheles species, and plasmodium vivax. Geographically, as per the WHO report, nearly half of the world's population was at risk in 2017, wherein the African region was the most affected one. Along with Africa, Asia Pacific region is also expected to grow at a considerable rate among all the other regions with Middle-east and Latin America likely to be the other potential regions for malaria vaccines market. North America and Europe have lower cases of malaria related diseases with regions such as Africa monitoring some of the highest deaths of children related to malaria globally.

Some of the major factors pushing the market include the expanding occurrences of malaria in addition to the existence of numerous companies that are introducing low profit margin vaccines throughout the world. Increasing awareness associated to the aftereffects of the disease, continuous R&D in this section and increased funding from the government of the developing and developed countries together is pushing the market for malaria vaccines globally. Weak supply chain and distribution network among some of the developing countries which are affected by malaria are creating restraints for the market growth in these regions, however companies and government organizations are working together to overcome this challenge. It is anticipated that the continuous R&D for malaria vaccines and the continuous growth of this disease will help the market to grow in the coming years.

A few key strategies adopted by companies operating in the malaria vaccines market are new technology and product development, and geographical expansion among the developing regions to focus on proving vaccines to the areas highly affected by the disease at lower cost. The leading players operating in the market globally are GlaxoSmithKline, GenVec, Inc., Nobelpharma, and Sanaria. Some other promising vendors are Cadila Healthcare Ltd., CellFree Sciences Co. Ltd., VLP Therapeutics LLC, and Genome ReS Ltd. among others.

Polaris Market Research has segmented the global malaria vaccines market on the basis of source type, application and region:

Malaria Vaccines Agent Type Outlook (Revenue, USD Million, 2015 - 2026)

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Anopheles Species

Malaria Vaccines Vaccine Type Outlook (Revenue, USD Million, 2015 - 2026)

  • Pre-Erythrocytic Vaccine
  • Erythrocytic Vaccine
  • Multi-antigen Vaccine

Malaria Vaccines Distribution Channel Type Outlook (Revenue, USD Million, 2015 - 2026)

  • Hospitals
  • Clinics
  • Community Centers

Malaria Vaccines Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East & Africa

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-away
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. Malaria Vaccines Market Insights

  • 3.1. Malaria Vaccines- Industry snapshot
  • 3.2. Malaria Vaccines-Ecosystem analysis
  • 3.3. Malaria Vaccines market dynamics
    • 3.3.1. Malaria Vaccines- Market Forces
      • 3.3.1.1. Malaria Vaccines Market driver analysis
      • 3.3.1.2. Malaria Vaccines Market restraint/challenges analysis
      • 3.3.1.3. Malaria Vaccines Market opportunity analysis
  • 3.4. Industry analysis - Porter's five force
    • 3.4.1. Bargaining power of supplier
    • 3.4.2. Bargaining power of buyer
    • 3.4.3. Threat of substitute
    • 3.4.4. Threat of new entrant
    • 3.4.5. Degree of competition
  • 3.5. Malaria Vaccines market PEST analysis, 2017
  • 3.6. Malaria Vaccines market Value Chain analysis
  • 3.7. Malaria Vaccines Industry trends
  • 3.8. Competitive Ranking Analysis

4. Malaria Vaccines Market Size and Forecast by Agent

  • 4.1. Key Findings
  • 4.2. Plasmodium Falciparum
    • 4.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 4.3. Plasmodium Vivax
    • 4.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 4.4. Anopheles Species
    • 4.4.1. Global Market Estimates and Forecasts, 2017-2026

5. Malaria Vaccines Market Size and Forecast by Vaccines Type

  • 5.1. Key Findings
  • 5.2. Pre-Erythrocytic Vaccine
    • 5.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 5.3. Erythrocytic Vaccine
    • 5.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 5.4. Multi-antigen Vaccine
    • 5.4.1. Global Market Estimates and Forecasts, 2017-2026

6. Malaria Vaccines Market Size and Forecast by Channel of Distribution

  • 6.1. Key Findings
  • 6.2. Hospitals
    • 6.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 6.3. Clinics
    • 6.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 6.4. Community Centers
    • 6.4.1. Global Market Estimates and Forecasts, 2017-2026

7. Malaria Vaccines Market Size and Forecast by Regions

  • 7.1. Key findings
  • 7.2. North America
    • 7.2.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 7.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 7.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.2.4. U.S.
      • 7.2.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.2.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.2.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.2.5. Canada
      • 7.2.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.2.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.2.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 7.3. Europe
    • 7.3.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 7.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 7.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.3.4. Germany
      • 7.3.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.3.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.3.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026

8.

  • 8.1.
    • 8.1.1. UK
      • 8.1.1.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.1.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.1.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.2. France
      • 8.1.2.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.3. Asia Pacific
      • 8.1.3.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.4. China
      • 8.1.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.5. India
      • 8.1.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.6. Japan
      • 8.1.6.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.6.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.6.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 8.2. Latin America
    • 8.2.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 8.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 8.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.2.4. Brazil
      • 8.2.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.2.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.2.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.2.5. Mexico
      • 8.2.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.2.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.2.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 8.3. Middle East & Africa
    • 8.3.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 8.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 8.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026

9. Company Profiles

  • 9.1. GlaxoSmithKline
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Developments
  • 9.2. GenVec, Inc.
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Developments
  • 9.3. Nobelpharma
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Developments
  • 9.4. Sanaria
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Developments
  • 9.5. Cadila Healthcare Ltd.
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments
  • 9.6. VLP Therapeutics LLC
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments
  • 9.7. CellFree Sciences Co. Ltd.
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments
  • 9.8. Genome ReS Ltd.
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments
Back to Top